JP2016135771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016135771A5 JP2016135771A5 JP2016001939A JP2016001939A JP2016135771A5 JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5 JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functional part
- antibody according
- sdr
- epidermidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 241000192125 Firmicutes Species 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 241001147736 Staphylococcus capitis Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241001147695 Staphylococcus caprae Species 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22587809P | 2009-07-15 | 2009-07-15 | |
| EP09165558 | 2009-07-15 | ||
| US61/225,878 | 2009-07-15 | ||
| EP09165558.9 | 2009-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Division JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Division JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016135771A JP2016135771A (ja) | 2016-07-28 |
| JP2016135771A5 true JP2016135771A5 (enExample) | 2016-12-22 |
Family
ID=41467048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
| JP2016001939A Pending JP2016135771A (ja) | 2009-07-15 | 2016-01-07 | グラム陽性菌特異的結合化合物 |
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US20110020323A1 (enExample) |
| EP (1) | EP2454284B1 (enExample) |
| JP (3) | JP6192294B2 (enExample) |
| KR (1) | KR101832201B1 (enExample) |
| CN (2) | CN102666583B (enExample) |
| AR (1) | AR077756A1 (enExample) |
| AU (2) | AU2010271582B2 (enExample) |
| BR (1) | BR112012000953A8 (enExample) |
| CA (1) | CA2768204A1 (enExample) |
| DK (1) | DK2454284T3 (enExample) |
| EA (1) | EA031447B1 (enExample) |
| ES (1) | ES2673323T3 (enExample) |
| HK (1) | HK1222418A1 (enExample) |
| HU (1) | HUE038277T2 (enExample) |
| IL (3) | IL217497A (enExample) |
| MX (1) | MX350234B (enExample) |
| NZ (2) | NZ598063A (enExample) |
| PL (1) | PL2454284T3 (enExample) |
| SG (2) | SG177653A1 (enExample) |
| SI (1) | SI2454284T1 (enExample) |
| TR (1) | TR201809128T4 (enExample) |
| TW (2) | TW201610153A (enExample) |
| WO (1) | WO2011008092A2 (enExample) |
| ZA (2) | ZA201200363B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| DK1974017T4 (da) | 2005-12-09 | 2023-09-25 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler |
| EP3683317A3 (en) | 2009-05-13 | 2020-09-30 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| DK2454283T3 (en) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics Bv | METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
| TR201809128T4 (tr) | 2009-07-15 | 2018-07-23 | Aimm Therapeutics Bv | Gram-pozitif bakterilere spesifik bağlanan bileşikler. |
| ES2626671T3 (es) * | 2010-12-02 | 2017-07-25 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| CN102559733A (zh) * | 2012-03-13 | 2012-07-11 | 黑龙江省科学院微生物研究所 | 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104968797B (zh) | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| WO2014142117A1 (ja) * | 2013-03-12 | 2014-09-18 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| BR112015029754A2 (pt) | 2013-05-31 | 2017-09-26 | Genentech Inc | anticorpos anti-teicoico da parede e conjugados |
| MA38686A1 (fr) * | 2013-05-31 | 2017-10-31 | Genentech Inc | Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés |
| AU2014323523B2 (en) | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| KR20240042192A (ko) | 2013-12-17 | 2024-04-01 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| WO2015115892A1 (en) | 2014-01-31 | 2015-08-06 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| JP6751393B2 (ja) * | 2014-12-03 | 2020-09-02 | ジェネンテック， インコーポレイテッド | 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用 |
| KR20170086536A (ko) * | 2014-12-03 | 2017-07-26 | 제넨테크, 인크. | 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도 |
| WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| KR102721137B1 (ko) | 2017-05-30 | 2024-10-25 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| CA3060984A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| US11280788B2 (en) | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
| KR102301987B1 (ko) * | 2019-11-14 | 2021-09-13 | 연세대학교 산학협력단 | 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트 |
| US20240101666A1 (en) | 2020-10-23 | 2024-03-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034655A2 (en) | 1994-06-07 | 1995-12-21 | The Rockefeller University | Surface protein of staphylococcus aureus |
| US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| CA2208780C (en) * | 1995-01-30 | 2010-03-30 | Peter Truog | Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747 |
| SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| WO2000012132A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| AU771426B2 (en) | 1998-08-31 | 2004-03-18 | Inhibitex, Inc. | Multicomponent vaccines |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| BR9913311A (pt) | 1998-08-31 | 2001-10-16 | Trinity College Dublin | Molécula de ácido nucleico isolado, ácido nucleico isolado, vetor, proteìna, anticorpo e anti-soros formados contra uma proteìna, kit de diagnóstico, processos para reduzir a infecção de estafilococos coagulase-negativos de um dispositivo médico de retenção, para tratar uma infecção de estafilococus coagulase-negativa, para prevenir uma infecção de estafilococos coagulase-negativa em um paciente, para induzir uma resposta imunológica e para identificar compostos que inibem estafilococos coagulase-negativos |
| US20030165527A1 (en) | 1998-12-22 | 2003-09-04 | Bengt Guss | Novel fibronectin-binding protein |
| US20040038327A1 (en) | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
| CN1489474A (zh) * | 2001-01-26 | 2004-04-14 | Ӣϣ��̩��˹��˾ | 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法 |
| GB0127983D0 (en) * | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| EP1540559B1 (en) | 2002-09-13 | 2013-02-27 | The Texas A & M University System | Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| US20040151737A1 (en) | 2003-02-05 | 2004-08-05 | University Of Tennessee | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
| WO2004080490A2 (en) | 2003-03-07 | 2004-09-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2526753A1 (en) | 2003-05-29 | 2004-12-23 | Inhibitex, Inc. | Sdr proteins from staphylococcus capitis and their use in preventing and treating infections |
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| EP1850867A1 (en) * | 2005-01-10 | 2007-11-07 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| WO2006138627A2 (en) | 2005-06-16 | 2006-12-28 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| WO2007100580A2 (en) | 2006-02-22 | 2007-09-07 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use |
| CN103351435B (zh) * | 2006-06-06 | 2015-08-19 | 克鲁塞尔荷兰公司 | 具有杀灭葡萄球菌活性的人结合分子及其应用 |
| US20100209434A1 (en) * | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| CN101302504B (zh) * | 2007-05-11 | 2011-12-21 | 上海高科联合生物技术研发有限公司 | 一种抗体亲和层析纯化溶葡萄球菌酶的方法 |
| ATE543835T1 (de) | 2007-07-16 | 2012-02-15 | Genentech Inc | Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren |
| ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| US20090162379A1 (en) | 2007-10-01 | 2009-06-25 | Magnus Hook | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor |
| AU2008312457B2 (en) | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| EA019516B1 (ru) | 2008-01-31 | 2014-04-30 | Де Провост, Феллоус Энд Сколарс Оф Де Колледж Оф Де Хоули Энд Андивайдид Тринити Оф Куин Элизабет, Неар Дублин | Лечение микробных инфекций |
| PT2247620T (pt) | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| WO2010005513A2 (en) | 2008-06-30 | 2010-01-14 | The Texas A&M University System | Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
| CN102481352A (zh) | 2009-06-22 | 2012-05-30 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的免疫原性组合物 |
| TR201809128T4 (tr) | 2009-07-15 | 2018-07-23 | Aimm Therapeutics Bv | Gram-pozitif bakterilere spesifik bağlanan bileşikler. |
| WO2011007004A1 (en) | 2009-07-16 | 2011-01-20 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Treatment of infections |
-
2010
- 2010-07-15 TR TR2018/09128T patent/TR201809128T4/tr unknown
- 2010-07-15 TW TW104126578A patent/TW201610153A/zh unknown
- 2010-07-15 EA EA201390967A patent/EA031447B1/ru not_active IP Right Cessation
- 2010-07-15 CA CA2768204A patent/CA2768204A1/en not_active Abandoned
- 2010-07-15 HU HUE10734844A patent/HUE038277T2/hu unknown
- 2010-07-15 SG SG2012002622A patent/SG177653A1/en unknown
- 2010-07-15 MX MX2014012186A patent/MX350234B/es unknown
- 2010-07-15 PL PL10734844T patent/PL2454284T3/pl unknown
- 2010-07-15 CN CN201080041138.6A patent/CN102666583B/zh not_active Expired - Fee Related
- 2010-07-15 DK DK10734844.3T patent/DK2454284T3/en active
- 2010-07-15 CN CN201510639968.3A patent/CN105440133A/zh active Pending
- 2010-07-15 SG SG10201704269RA patent/SG10201704269RA/en unknown
- 2010-07-15 WO PCT/NL2010/050456 patent/WO2011008092A2/en not_active Ceased
- 2010-07-15 NZ NZ598063A patent/NZ598063A/en not_active IP Right Cessation
- 2010-07-15 TW TW099123405A patent/TWI502068B/zh not_active IP Right Cessation
- 2010-07-15 AU AU2010271582A patent/AU2010271582B2/en not_active Ceased
- 2010-07-15 KR KR1020127003839A patent/KR101832201B1/ko not_active Expired - Fee Related
- 2010-07-15 ES ES10734844.3T patent/ES2673323T3/es active Active
- 2010-07-15 SI SI201031701T patent/SI2454284T1/en unknown
- 2010-07-15 NZ NZ616921A patent/NZ616921A/en not_active IP Right Cessation
- 2010-07-15 EP EP10734844.3A patent/EP2454284B1/en not_active Not-in-force
- 2010-07-15 JP JP2012520555A patent/JP6192294B2/ja not_active Expired - Fee Related
- 2010-07-15 US US12/837,358 patent/US20110020323A1/en not_active Abandoned
- 2010-07-15 AR ARP100102587A patent/AR077756A1/es unknown
- 2010-07-15 BR BR112012000953A patent/BR112012000953A8/pt not_active Application Discontinuation
-
2011
- 2011-11-28 US US13/305,659 patent/US8617556B2/en not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217497A patent/IL217497A/en not_active IP Right Cessation
- 2012-01-17 ZA ZA2012/00363A patent/ZA201200363B/en unknown
-
2013
- 2013-03-05 US US13/786,206 patent/US9399673B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/786,215 patent/US9090677B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,715 patent/US9266943B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 ZA ZA2014/00644A patent/ZA201400644B/en unknown
-
2015
- 2015-04-01 IL IL238074A patent/IL238074A/en not_active IP Right Cessation
- 2015-06-02 US US14/728,826 patent/US9458228B2/en not_active Expired - Fee Related
- 2015-10-22 IL IL242207A patent/IL242207A0/en unknown
- 2015-12-28 US US14/981,643 patent/US9688745B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001939A patent/JP2016135771A/ja active Pending
- 2016-08-24 US US15/246,301 patent/US9927428B2/en not_active Expired - Fee Related
- 2016-09-05 HK HK16110533.5A patent/HK1222418A1/zh unknown
- 2016-10-27 AU AU2016250398A patent/AU2016250398B2/en not_active Ceased
-
2018
- 2018-02-20 US US15/900,589 patent/US20180292391A1/en not_active Abandoned
- 2018-04-04 JP JP2018072444A patent/JP2018134089A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA) | |
| Vuong et al. | Investigational drugs to treat methicillin-resistant Staphylococcus aureus | |
| Assis et al. | New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus | |
| Saylor et al. | Monoclonal antibody-based therapies for microbial diseases | |
| Del Rio et al. | Patients at risk of complications of Staphylococcus aureus bloodstream infection | |
| Gould et al. | New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance | |
| JP2021063090A5 (enExample) | ||
| Ohlsen et al. | Immunotherapeutic strategies to combat staphylococcal infections | |
| Berry et al. | Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology | |
| Munita et al. | Enterococcal endocarditis: can we win the war? | |
| JP2012518624A5 (enExample) | ||
| JP2017519768A5 (enExample) | ||
| SG10201811361XA (en) | Treatment of polybacterials infections | |
| SI2454284T1 (en) | Compounds that specifically bind to Gram-positive bacteria | |
| Varshney et al. | Humanized staphylococcal enterotoxin B (SEB)–specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| JP2018121640A5 (enExample) | ||
| JP2006514636A5 (enExample) | ||
| François et al. | Antibody-based therapy to combat Staphylococcus aureus infections | |
| JP2011526887A5 (enExample) | ||
| WO2017137954A3 (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
| Rezazadeh et al. | Antibiotic profile of methicillin-resistant Staphylococcus aureus with multiple-drug resistances isolated from nosocomial infections in Vali-Asr Hospital of Arak | |
| JP2024009968A5 (enExample) | ||
| Cunha et al. | Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy | |
| Castanheira et al. | 690. Activity of a novel polymyxin analog, QPX9003, tested against resistant Gram-negative pathogens, including carbapenem-resistant Acinetobacter, Enterobacterales, and Pseudomonas |